Drugs / Pelabresib
Pelabresib
also known as
CPI-0610 · CPI-0610 ANHYDROUS · CPI-232 · CPI-267232 · PELABRESIB (CPI-0610) · PELABRESIB ANHYDROUS · Pelabresib monohydrate
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07783503 | Sep → Nov 2026 expected | — | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07340190 | Jun 2026 → Mar 2028 expected | cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07422610 | May 2026 → Jun 2028 expected | — | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07340138 | Apr → Jul 2026 overdue | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05391022 | Jul 2021 → Mar 2023 | cancer, hematopoietic and lymphoid cell neoplasm | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02157636 | Jul 2014 → Nov 2016 | plasma cell myeloma | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01949883 | Sep 2013 → Dec 2017 | lymphoma | Constellation Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02158858 | Jul 2014 → Jan 2025 | acute myeloid leukemia, essential thrombocythemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +3 | Constellation Pharmaceuticals | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT02986919 | May 2017 → May 2018 | peripheral nervous system neoplasm | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT07357727 | May 2026 → May 2028 expected | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06401356 | Aug 2024 → Jun 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT04603495 | Apr 2021 → Aug 2023 overdue | myelofibrosis, primary myelofibrosis | Novartis Pharmaceuticals | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-25 | Novartis Pharmaceuticals | Results Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS novartis.com ↗
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-25 | Novartis Pharmaceuticals | Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS novartis.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pelabresib | “In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling and demonstrated antitumor activity in vitro.” PMID 36923307 ↗ Aug 2022 |
| Known as | CPI-0610 | “In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-κB signaling and demonstrated antitumor activity in vitro.” PMID 36923307 ↗ Aug 20223“Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)” NCT04603495 ↗ |
| Known as | CPI-0610 ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303404 ↗ |
| Known as | CPI-232 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303404 ↗ |
| Known as | CPI-267232 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303404 ↗ |
| Known as | PELABRESIB (CPI-0610) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303404 ↗ |
| Known as | PELABRESIB ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303404 ↗ |
| Known as | Pelabresib monohydrate | “Pelabresib monohydrate tablets + ruxolitinib phosphate tablets” NCT04603495 ↗ |
| Action | Inhibit | “CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.” NCT01949883 ↗ |
| Modality | Small molecule | “CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.” NCT01949883 ↗ |
| Route | Oral | “doses of pelabresib orally once daily” PMID 36923307 ↗ Aug 2022 |